Sanofi's Deal With Medco/UBC Seeks Payer Perspective To Inform Drug R&D, Marketing
This article was originally published in The Pink Sheet Daily
The multi-year, global data, research and consulting agreement will focus primarily on drugs in Phase II or III.
You may also be interested in...
Projects include creation of an enhanced “core value dossier” supporting reimbursement for a novel oncology drug and development of a “relative medical value index” framework to help prioritize pipeline projects and highlight opportunities to expand an individual drug study plan to address payer needs.
As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.